Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD)....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 6 June 2026
2017-12-01 06:30:00 Friday ET

Dr Kai-Fu Lee praises China as the next epicenter of artificial intelligence, smart data analysis, and robotic automation. With prior IT careers at Apple, M
2018-05-11 09:37:00 Friday ET

OPEC countries have cut the global glut of oil production in recent years while the resultant oil price has surged from $30 to $78 per barrel from 2015 to 2
2018-11-03 11:36:00 Saturday ET

Apple adds fresh features to its new iPad Pro and MacBook Air in addition to its prior suite of iPhone XS, iPhone XS Max, and iPhone XR back in September 20
2022-05-30 09:32:00 Monday ET

The new semiconductor microchip demand-supply imbalance remains quite severe for the U.S. tech and auto industries. Our current fundamental macro a
2019-07-03 11:35:00 Wednesday ET

U.S. regulatory agencies may consider broader economic issues in their antitrust probe into tech titans such as Amazon, Apple, Facebook, and Google etc. Hou
2019-02-28 12:39:00 Thursday ET

New York Fed CEO John Williams sees no need to raise the interest rate unless economic growth or inflation rises to a high gear. After raising the interest